Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 1.46B |
| Revenue (ttm) | 22.88M |
| Net Income (ttm) | -89.09M |
| Shares Out | 44.43M |
| EPS (ttm) | -2.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 161,523 |
| Open | 34.52 |
| Previous Close | 34.75 |
| Day's Range | 32.84 - 34.75 |
| 52-Week Range | 21.53 - 52.38 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 49.17 (+49.7%) |
| Est. Earnings Date | Oct 13, 2021 |
About NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally ava...
Financial Performance
In 2020, NRIX's revenue was $17.82 million, a decrease of -42.73% compared to the previous year's $31.12 million. Losses were -$43.24 million, 99.3% more than in 2019.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is 49.17, which is an increase of 49.68% from the latest price.
News
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies
Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President,...
SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff ...
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reductio...
Orally available NX-5948 is a potent selective degrader of Bruton's Tyrosine Kinase (BTK) without IMiD activity
Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors
SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Cla...
Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a mode...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of Nurix ...
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands,...
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex's Lemonade Stand Foundation-funded $18.5 million Crazy 8 ...
Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR
CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade
Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to ...
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its un...
Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M....
Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its un...
Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock
SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced...
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update
First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies
Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein D...
Expansion of agreement results in an additional payment of $22 million to Nurix Expansion of agreement results in an additional payment of $22 million to Nurix
Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
Data support a planned clinical trial of NX-2127 in B-cell malignancies Data support a planned clinical trial of NX-2127 in B-cell malignancies
Nurix Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be prese...
Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 6...
SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present d...
Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation...
SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph.D. has res...
Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update
Completed recent IPO raising approximately $238 .5 million in gross proceeds
Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit
SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3...
Nurix Therapeutics shares slide 2.3% in trading debut
Nurix Therapeutics Inc. shares nrix fell 2.3% in their trading debut Friday, after pricing above the proposed price range.